MGI(SH:688114) 仪器信息网·2025-05-04 15:17Core Viewpoint - BGI Genomics achieved a main business revenue of 2.957 billion yuan in 2024, with the sequencing instrument business contributing 2.348 billion yuan, reflecting a strategic focus on product innovation and market leadership in the domestic sequencing instrument sector [4][10]. Revenue Breakdown - The revenue from the gene sequencing instrument business reached 2.348 billion yuan, a year-on-year increase of 2.47%. The revenue from instrument equipment was 960 million yuan, up 6.92%, while reagent consumables generated 1.373 billion yuan, growing by 1.43% [4]. - The laboratory automation business generated 209 million yuan, showing a significant growth of 36.69% compared to 2023, excluding impacts from public health events [4]. - New business segments contributed 400 million yuan, with a year-on-year growth of 57.05%, also excluding public health event impacts [4]. Product Innovation - BGI Genomics launched a series of new sequencing instruments and reagents, establishing a comprehensive SEQ ALL matrix. The company is the first globally to have large-scale commercial production of both short-read and long-read sequencing products [5][6]. - New products include the StandardMPS 2.0 sequencing reagent, which enhances high-throughput sequencing quality to Q40 accuracy, and the DNBSEQ-E25 Flash sequencing instrument, which significantly accelerates sequencing speed while reducing error rates [6]. AI Integration - The company implemented an intelligent transformation in its laboratory automation business by integrating AI technology, creating a standardized library of functional modules for life science tools, enhancing operational efficiency and decision-making processes [7]. Multi-Omics Tools Development - BGI Genomics is advancing multi-omics tools to support high-throughput, low-cost omics data production, addressing key scientific questions in life sciences. Significant progress has been made in cell genomics, spatial genomics, and imaging [8]. - In cell genomics, the company released new preservation solutions and upgraded single-cell library preparation kits, becoming one of the few companies globally to offer a comprehensive range of single-cell applications [8]. Market Performance - In the domestic market, the revenue from gene sequencing instruments reached 1.607 billion yuan, a year-on-year increase of 11.37%, capturing a 39% market share in the upstream revenue of the domestic gene sequencing industry [10]. - The company installed over 1,000 new sequencing instruments in the domestic market, representing a 63.8% share of new installations in the domestic gene sequencing industry [10]. - In overseas markets, the revenue from gene sequencing instruments was 741 million yuan, a decline of 12.66%. The company faced challenges in the Asia-Pacific and Europe-Africa regions due to project delays and increased competition, while the Americas region saw an 8.28% revenue increase [11].